Supplier nitrosamine control weak during regulatory inspection – FDA/EMA nitrosamine expectations
Weak Control of Supplier Nitrosamines During Regulatory Inspections: A Comprehensive Playbook The emergence of nitrosamines as potential impurities in pharmaceutical products has raised significant regulatory scrutiny. Both the FDA and…